TY - JOUR
T1 - Patient Assisted Intervention for Neuropathy
T2 - Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial
AU - Barohn, Richard J.
AU - Gajewski, Byron
AU - Pasnoor, Mamatha
AU - Brown, Alexandra
AU - Herbelin, Laura L.
AU - Kimminau, Kim S.
AU - Mudaranthakam, Dinesh Pal
AU - Jawdat, Omar
AU - Dimachkie, Mazen M.
AU - Iyadurai, Stanley
AU - Stino, Amro
AU - Kissel, John
AU - Pascuzzi, Robert
AU - Brannagan, Thomas
AU - Wicklund, Matthew
AU - Ahmed, Aiesha
AU - Walk, David
AU - Smith, Gordon
AU - Quan, Dianna
AU - Heitzman, Darryl
AU - Tobon, Alejandro
AU - Ladha, Shafeeq
AU - Wolfe, Gil
AU - Pulley, Michael
AU - Hayat, Ghazala
AU - Li, Yuebing
AU - Thaisetthawatkul, Pariwat
AU - Lewis, Richard
AU - Biliciler, Suur
AU - Sharma, Khema
AU - Salajegheh, Kian
AU - Trivedi, Jaya
AU - Mallonee, William
AU - Burns, Ted
AU - Jacoby, Mark
AU - Bril, Vera
AU - Vu, Tuan
AU - Ramchandren, Sindhu
AU - Bazant, Mark
AU - Austin, Sara
AU - Karam, Chafic
AU - Hussain, Yessar
AU - Kutz, Christen
AU - Twydell, Paul
AU - Scelsa, Stephen
AU - Kushlaf, Hani
AU - Wymer, James
AU - Hehir, Michael
AU - Kolb, Noah
AU - Ralph, Jeffrey
AU - Barboi, Alexandru
AU - Verma, Navin
AU - Ahmed, Moiz
AU - Memon, Anza
AU - Saperstein, David
AU - Lou, Jau Shin
AU - Swenson, Andrea
AU - Cash, Tiyonnoh
N1 - Publisher Copyright:
© 2020 American Medical Association. All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Importance: Cryptogenic sensory polyneuropathy (CSPN) is a common generalized slowly progressive neuropathy, second in prevalence only to diabetic neuropathy. Most patients with CSPN have significant pain. Many medications have been tried for pain reduction in CSPN, including antiepileptics, antidepressants, and sodium channel blockers. There are no comparative studies that identify the most effective medication for pain reduction in CSPN. Objective: To determine which medication (pregabalin, duloxetine, nortriptyline, or mexiletine) is most effective for reducing neuropathic pain and best tolerated in patients with CSPN. Design, Setting, and Participants: From December 1, 2014, through October 20, 2017, a bayesian adaptive, open-label randomized clinical comparative effectiveness study of pain in 402 participants with CSPN was conducted at 40 neurology care clinics. The trial included response adaptive randomization. Participants were patients with CSPN who were 30 years or older, with a pain score of 4 or greater on a numerical rating scale (range, 0-10, with higher scores indicating a higher level of pain). Participant allocation to 1 of 4 drug groups used the utility function and treatment's sample size for response adaptation randomization. At each interim analysis, a decision was made to continue enrolling (up to 400 participants) or stop the whole trial for success (80% power). Patient engagement was maintained throughout the trial, which helped guide the study and identify ways to communicate and disseminate information. Analysis was performed from December 11, 2015, to January 19, 2018. Interventions: Participants were randomized to receive nortriptyline (n = 134), duloxetine (n = 126), pregabalin (n = 73), or mexiletine (n = 69). Main Outcomes and Measures: The primary outcome was a utility function that was a composite of the efficacy (participant reported pain reduction of ≥50% from baseline to week 12) and quit (participants who discontinued medication) rates. Results: Among the 402 participants (213 men [53.0%]; mean [SD] age, 60.1 [13.4] years; 343 White [85.3%]), the utility function of nortriptyline was 0.81 (95% bayesian credible interval [CrI], 0.69-0.93; 34 of 134 [25.4%] efficacious; and 51 of 134 [38.1%] quit), of duloxetine was 0.80 (95% CrI, 0.68-0.92; 29 of 126 [23.0%] efficacious; and 47 of 126 [37.3%] quit), pregabalin was 0.69 (95% CrI, 0.55-0.84; 11 of 73 [15.1%] efficacious; and 31 of 73 [42.5%] quit), and mexiletine was 0.58 (95% CrI, 0.42-0.75; 14 of 69 [20.3%] efficacious; and 40 of 69 [58.0%] quit). The probability each medication yielded the highest utility was 0.52 for nortriptyline, 0.43 for duloxetine, 0.05 for pregabalin, and 0.00 for mexiletine. Conclusions and Relevance: This study found that, although there was no clearly superior medication, nortriptyline and duloxetine outperformed pregabalin and mexiletine when pain reduction and undesirable adverse effects are combined to a single end point. Trial Registration: ClinicalTrials.gov Identifier: NCT02260388.
AB - Importance: Cryptogenic sensory polyneuropathy (CSPN) is a common generalized slowly progressive neuropathy, second in prevalence only to diabetic neuropathy. Most patients with CSPN have significant pain. Many medications have been tried for pain reduction in CSPN, including antiepileptics, antidepressants, and sodium channel blockers. There are no comparative studies that identify the most effective medication for pain reduction in CSPN. Objective: To determine which medication (pregabalin, duloxetine, nortriptyline, or mexiletine) is most effective for reducing neuropathic pain and best tolerated in patients with CSPN. Design, Setting, and Participants: From December 1, 2014, through October 20, 2017, a bayesian adaptive, open-label randomized clinical comparative effectiveness study of pain in 402 participants with CSPN was conducted at 40 neurology care clinics. The trial included response adaptive randomization. Participants were patients with CSPN who were 30 years or older, with a pain score of 4 or greater on a numerical rating scale (range, 0-10, with higher scores indicating a higher level of pain). Participant allocation to 1 of 4 drug groups used the utility function and treatment's sample size for response adaptation randomization. At each interim analysis, a decision was made to continue enrolling (up to 400 participants) or stop the whole trial for success (80% power). Patient engagement was maintained throughout the trial, which helped guide the study and identify ways to communicate and disseminate information. Analysis was performed from December 11, 2015, to January 19, 2018. Interventions: Participants were randomized to receive nortriptyline (n = 134), duloxetine (n = 126), pregabalin (n = 73), or mexiletine (n = 69). Main Outcomes and Measures: The primary outcome was a utility function that was a composite of the efficacy (participant reported pain reduction of ≥50% from baseline to week 12) and quit (participants who discontinued medication) rates. Results: Among the 402 participants (213 men [53.0%]; mean [SD] age, 60.1 [13.4] years; 343 White [85.3%]), the utility function of nortriptyline was 0.81 (95% bayesian credible interval [CrI], 0.69-0.93; 34 of 134 [25.4%] efficacious; and 51 of 134 [38.1%] quit), of duloxetine was 0.80 (95% CrI, 0.68-0.92; 29 of 126 [23.0%] efficacious; and 47 of 126 [37.3%] quit), pregabalin was 0.69 (95% CrI, 0.55-0.84; 11 of 73 [15.1%] efficacious; and 31 of 73 [42.5%] quit), and mexiletine was 0.58 (95% CrI, 0.42-0.75; 14 of 69 [20.3%] efficacious; and 40 of 69 [58.0%] quit). The probability each medication yielded the highest utility was 0.52 for nortriptyline, 0.43 for duloxetine, 0.05 for pregabalin, and 0.00 for mexiletine. Conclusions and Relevance: This study found that, although there was no clearly superior medication, nortriptyline and duloxetine outperformed pregabalin and mexiletine when pain reduction and undesirable adverse effects are combined to a single end point. Trial Registration: ClinicalTrials.gov Identifier: NCT02260388.
UR - http://www.scopus.com/inward/record.url?scp=85089962348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089962348&partnerID=8YFLogxK
U2 - 10.1001/jamaneurol.2020.2590
DO - 10.1001/jamaneurol.2020.2590
M3 - Article
C2 - 32809014
AN - SCOPUS:85089962348
SN - 2168-6149
VL - 78
SP - 68
EP - 76
JO - JAMA Neurology
JF - JAMA Neurology
IS - 1
ER -